Life Biosciences announced it has treated the first participant in a gene therapy trial aiming to partially reprogram aged cells to a younger-like state. The approach turns on three genes intended to “partially reprogram” adult cells and test safety while exploring potential regeneration of optic-nerve neurons in glaucoma. The company framed the eye as an initial target where catastrophic systemic risks may be lower than in other organs. The study will evaluate whether the proteins encoded by the activated genes can support regeneration in a tissue where adult neurons typically do not regrow. Partial reprogramming has drawn scientific attention for possible rejuvenation uses, but the field remains cautious because earlier work in animals raised concerns about potential malignant transformation risk if reprogramming proceeds too far. The first-patient dosing is a notable milestone for longevity-adjacent therapeutics crossing into disease-focused clinical testing.